Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. Issue 4 (6th October 2017)

• Record Type: Journal Article
• Authors: Shao, Yongfu; Lu, Rongdan; Yang, Yunben; Xu, Qiancheng; Wang, Bojun; Ye, Guoliang
• Is Part Of: Journal of clinical laboratory analysis. Volume 32:Issue 4(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-10-06
• Subjects: antibiotic resistance -- gender -- Helicobacter pylori; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.22339
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract : Background: Resistance of Helicobacter pylori ( H. pylori ) to antibiotics is increasing worldwide. To determine the status of H. pylori resistance and its patterns in clinical patients, an investigation utilizing susceptibility testing for commonly used antibiotics was needed. Methods: Total of 2283 H. pylori strains were collected from 2013 to 2016. The resistance and its patterns of these strains were tested by agar dilution method. The resistance rate and minimal inhibition concentration (MIC) in different gender groups were also analyzed. Results: The overall resistance rates were as following: amoxicillin (1.58%), clarithromycin (22.73%), levofloxacin (24.75%), furazolidone (1.49%), doxycycline (9.20%), cefetamet (97.20%), ceftriaxone (49.60%), cefuroxime (25.20%), gentamicin (3.73%), azithromycin (85.60%), rifampicin (2.80%), metronidazole (92.53%), ornidazole (94.27%), tinidazole (87.20%), ciprofloxacin (43.20%), and moxifloxacin (38.53%). There were only 64.08% strains pan‐susceptible to amoxicillin, clarithromycin, levofloxacin, and furazolidone, followed by mono resistance (23.17%), double resistance (11.13%), triple resistance (1.36%), and quadruple resistance (0.26%). Significant differences in the resistance rate and MIC were also observed in different gender groups. Conclusion: Antibiotic resistance trends of H. pylori is increasing in clinical patients. With the increasing resistance, it is imperative to individualized therapy based on the results of drug susceptibility testing.